The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer.

På svenska

Author

  • Rikard Larsson
  • Nigel Mongan
  • M C Johansson
  • Liliya Shcherbina
  • Per-Anders Abrahamsson
  • L Gudas
  • Olov Sterner
  • Jenny L Persson

Summary, in English

Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial and time-limited response to therapy before the cancer progresses and the patient succumbs to the disease. Despite recent advances in early diagnosis and treatment, approximately one-third of treated patients will relapse and become resistant to currently available treatments. In this review we evaluate current treatment practices and recent advances in therapy for localized prostate malignancy and advanced, metastatic prostate cancer. Some of the promising new drugs for PCa treatment include MDV3100, an androgen receptor (AR) antagonist that prevents androgens from binding to the AR and nuclear translocation and co-activator recruitment of the ligand-receptor complex; abiraterone, an orally administered drug that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17; and several newer cytotoxic drugs (epothilones, satraplatin). Key new insights are that cancer stem cells play a role in PCa and that PCa cells are dependent on the AR for proliferation, even in the hormone refractory state of the disease. We also discuss potential molecular targets for new drug candidates for the treatment of metastatic PCa.

Department/s

Publishing year

2011

Language

English

Pages

4440-4453

Publication/Series

Current Medicinal Chemistry

Volume

18

Document type

Journal article

Publisher

Bentham Science Publishers

Topic

  • Medicinal Chemistry

Status

Published

Research group

  • Experimental Cancer Research, Malmö
  • Neuroendocrine Cell Biology
  • Urological research, Malmö

ISBN/ISSN/Other

  • ISSN: 0929-8673